An injectable HIV-prevention drug is highly effective — but wildly expensive
Lenacapavir, a long-acting HIV-prevention drug, showed 89% more effectiveness than daily oral medication in clinical trials, raising hopes for broad, equitable rollout to combat HIV. However, its high cost poses a challenge, with no indication yet of a different price for PrEP use.
Reference News
Lenacapavir, a long-acting HIV-prevention drug requiring dosing every six months, showed 89% more effectiveness than daily oral medication in preventing HIV among gay, bisexual, and transgender individuals, and 100% effectiveness in cisgender women. Despite its potential to significantly reduce HIV infections, concerns over its high cost may hinder widespread adoption.
Lenacapavir, a long-acting HIV-prevention drug, showed 89% more effectiveness than daily oral medication in clinical trials, raising hopes for broad, equitable rollout to combat HIV. However, its high cost poses a challenge, with no indication yet of a different price for PrEP use.